The European Lead Factory, Europe’s largest collaborative drug discovery platform, continues its success story
The European Lead Factory (ELF) secured a total project budget of EUR 36.5 million under the second framework of the Innovative Medicines Initiative (IMI). Over the next 5 years, 20 partners in 7 countries will push forward the transformation of potential drug targets to new medicines in the new project ESCulab (European Screening Centre: unique library for attractive biology) under the European Lead Factory brand.
Read more
New at Pivot Park – Cytura Therapeutics
Recently Cytura Therapeutics opened the doors to its laboratory at Pivot Park. Cytura Therapeutics is focused on Developing a new class of drugs targeting genomic instability in cancer. Cytura Therapeutics is founded by Dr Ad van Gorp, former CEO of Lead Pharma, the Centre for Drug Design and Discovery (CD3) of the KU Leuven and Amsterdam UMC.
Read more
Voucher gives rise to collaboration
Synaffix has developed a new technology for targeted anti-cancer therapy. Specifically, Synaffix has improved the therapeutic window of an antibody-drug...
Read more
Synaffix Announces License Agreement worth up to $125 million with Leading Chinese ADC Developer, Shanghai Miracogen
Synaffix B.V., a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the...
Read more
New at Pivot Park – Absano
AbSano develops novel antibodies for innovative diagnostic tools as well as therapeutic purposes. “Our current projects involve the identification and...
Read more
BioConnection invests in expansion of its current production capacity with a second production line
BioConnection will invest €12 million in a second, commercial scale, manufacturing line to keep up with the growing customer demand...
Read more
A cup of coffee with….Lonneke Meijerink (Pivot Park)
Since March Lonneke started working at the Pivot Park Site Organisation as financial accountant. “After studying Business Economics at Tilburg...
Read more
Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem’s oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced today that it has entered into a research collaboration with Glycostem Therapeutics BV to explore the potential synergies of using Phio's self-delivering RNAi technology (sd-rxRNA®) in combination with Glycostem's proprietary Natural Killer-cell (NK-cell) generation technology (oNKord®) to develop cellular immunotherapies for cancer treatment with enhanced efficacy and/or safety.
Read more
Pharming announces a provisional commitment to invest in a minority stake in its fill & finish partner BioConnection BV
Pharming Group N.V. announces that it has made a provisional commitment to invest up to €1.6 million in cash and...
Read more